Page 1 | Search Results | Diabetes Care | American Diabetes Association

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Different Lipid Variables Predict Incident Coronary Artery Disease in Patients With Type 1 Diabetes With or Without Diabetic Nephropathy: The FinnDiane Study

Nina Tolonen, Carol Forsblom, Ville-Petteri Mäkinen, Valma Harjutsalo, Daniel Gordin, Maija Feodoroff, Niina Sandholm, Lena M. Thorn, Johan Wadén, Marja-Riitta Taskinen, Per-Henrik Groop

Diabetes Care 2014;37(8):2374–2382

https://doi.org/10.2337/dc13-2873

Published: 12 July 2014

View article titled, Different Lipid Variables Predict Incident Coronary Artery Disease in Patients With Type 1 Diabetes With or Without Diabetic Nephropathy: The FinnDiane Study

Includes: Supplementary data

Journal Articles

HDL-C and HDL-C/ApoA-I Predict Long-Term Progression of Glycemia in Established Type 2 Diabetes

Boris Waldman, Alicia J. Jenkins, Timothy M.E. Davis, Marja-Riitta Taskinen, Russell Scott, Rachel L. O’Connell, Val J. Gebski, Martin K.C. Ng, Anthony C. Keech

Diabetes Care 2014;37(8):2351–2358

https://doi.org/10.2337/dc13-2738

Published: 12 July 2014

View article titled, HDL-C and HDL-C/ApoA-I Predict Long-Term Progression of Glycemia in Established Type 2 Diabetes

Journal Articles

Glycemic Control Over 5 Years in 4,900 People With Type 2 Diabetes: Real-world diabetes therapy in a clinical trial cohort

James D. Best, MD, Paul L. Drury, FRACP, Timothy M.E. Davis, MRCP, Marja-Riitta Taskinen, MD, Y. Antero Kesäniemi, MD, Russell Scott, PHD, Christopher Pardy, BSC, Merryn Voysey, MBIOSTAT, Anthony C. Keech, FRACP, on behalf of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators

Diabetes Care 2012;35(5):1165–1170

https://doi.org/10.2337/dc11-1307

Published: 11 April 2012

View article titled, Glycemic Control Over 5 Years in 4,900 People With Type 2 Diabetes: <subtitle>Real-world diabetes therapy in a clinical trial cohort</subtitle>

Includes: Supplementary data

Journal Articles

Effects of Exenatide on Measures of β-Cell Function After 3 Years in Metformin-Treated Patients With Type 2 Diabetes

Mathijs C. Bunck, MD, Anja Cornér, MD, Bjorn Eliasson, MD, Robert J. Heine, MD, Rimma M. Shaginian, MD, Marja-Riitta Taskinen, MD, Ulf Smith, MD, Hannele Yki-Järvinen, MD, Michaela Diamant, MD

Diabetes Care 2011;34(9):2041–2047

https://doi.org/10.2337/dc11-0291

Published: 19 August 2011

View article titled, Effects of Exenatide on Measures of β-Cell Function After 3 Years in Metformin-Treated Patients With Type 2 Diabetes

Includes: Supplementary data

Journal Articles

Exenatide Affects Circulating Cardiovascular Risk Biomarkers Independently of Changes in Body Composition

Mathijs C. Bunck, MD, Michaela Diamant, MD, PHD, Bjorn Eliasson, MD, PHD, Anja Cornér, MD, Rimma M. Shaginian, MD, Robert J. Heine, MD, PHD, FRCP, Marja-Riitta Taskinen, MD, PHD, Hannele Yki-Järvinen, MD, PHD, FRCP, Ulf Smith, MD, PHD, FRCP

Diabetes Care 2010;33(8):1734–1737

https://doi.org/10.2337/dc09-2361

Published: 27 April 2010

View article titled, Exenatide Affects Circulating Cardiovascular Risk Biomarkers Independently of Changes in Body Composition

Includes: Supplementary data

Journal Articles

Effects of Long-Term Fenofibrate Treatment on Markers of Renal Function in Type 2 Diabetes: The FIELD Helsinki substudy

Carol Forsblom, DMSC, Anne Hiukka, MD, Eeva S. Leinonen, MD, PHD, Jouko Sundvall, MSC, Per-Henrik Groop, MD, PHD, Marja-Riitta Taskinen, MD, PHD

Diabetes Care 2010;33(2):215–220

https://doi.org/10.2337/dc09-0621

Published: 21 October 2009

View article titled, Effects of Long-Term Fenofibrate Treatment on Markers of Renal Function in Type 2 Diabetes: <subtitle>The FIELD Helsinki substudy</subtitle>

Includes: Supplementary data

Journal Articles

Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

Russell Scott, MB CHB, PHD, FRACP, Richard O'Brien, MB, PHD, FRACP, Greg Fulcher, MB, MD, FRACP, Chris Pardy, Michael d'Emden, MB BS, PHD, FRACP, Dana Tse, PHD, Marja-Riitta Taskinen, MD, Christian Ehnholm, MD, PHD, Anthony Keech, MB BS, FRACP, MSC(EPID), on behalf of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators

Diabetes Care 2009;32(3):493–498

https://doi.org/10.2337/dc08-1543

Published: 01 March 2009

View article titled, Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome: <subtitle>The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study</subtitle>

Includes: Supplementary data

Journal Articles

One-Year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients: A randomized, controlled trial

Mathijs C. Bunck, MD, Michaela Diamant, MD, PHD, Anja Cornér, MD, Bjorn Eliasson, MD, PHD, Jaret L. Malloy, PHD, Rimma M. Shaginian, MD, Wei Deng, PHD, David M. Kendall, MD, Marja-Riitta Taskinen, MD, PHD, Ulf Smith, MD, PHD, FRCP, Hannele Yki-Järvinen, MD, PHD, FRCP, Robert J. Heine, MD, PHD, FRCP

Diabetes Care 2009;32(5):762–768

https://doi.org/10.2337/dc08-1797

Published: 05 February 2009

View article titled, One-Year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients: <subtitle>A randomized, controlled trial</subtitle>

Includes: Supplementary data

Journal Articles

The Increase of Apolipoprotein A-V During Postprandial Lipemia Parallels the Response of Triglyceride-Rich Lipoproteins in Type 2 Diabetes: No relationship between apoA-V and postheparin plasma lipolytic activity

Juhani Kahri, MD, PHD, Jamila Fruchart-Najib, PHD, Niina Matikainen, MD, PHD, Jean-Charles Fruchart, MD, PHD, Juha Vakkilainen, MD, PHD, Marja-Riitta Taskinen, MD

Diabetes Care 2007;30(8):2083–2085

https://doi.org/10.2337/dc07-0100

Published: 01 August 2007

View article titled, The Increase of Apolipoprotein A-V During Postprandial Lipemia Parallels the Response of Triglyceride-Rich Lipoproteins in Type 2 Diabetes: <subtitle>No relationship between apoA-V and postheparin plasma lipolytic activity</subtitle>

Journal Articles

Serum Lipids and the Progression of Nephropathy in Type 1 Diabetes

Merlin C. Thomas, MBCHB, PHD, FRACP, Milla Rosengård-Bärlund, MD, Vashti Mills, BSC, Mats Rönnback, MD, Stephen Thomas, PHD, MRCP, Carol Forsblom, MD, DMSC, Mark E. Cooper, MBBS, PHD, Marja-Riitta Taskinen, MD, DMSC, Giancarlo Viberti, MD, FRCP, Per-Henrik Groop, MD, DMSC

Diabetes Care 2006;29(2):317–322

https://doi.org/10.2337/diacare.29.02.06.dc05-0809

Published: 01 February 2006

View article titled, Serum Lipids and the Progression of Nephropathy in Type 1 Diabetes

Includes: Supplementary data

Journal Articles

Metabolic Syndrome in Type 1 Diabetes: Association with diabetic nephropathy and glycemic control (the FinnDiane study)

Lena M. Thorn, MD, Carol Forsblom, MD, DMSC, Johan Fagerudd, MD, DMSC, Merlin C. Thomas, MD, PHD, Kim Pettersson-Fernholm, MD, DMSC, Markku Saraheimo, MD, Johan Wadén, MD, Mats Rönnback, MD, Milla Rosengård-Bärlund, MD, Clas-Göran af Björkesten, MD, Marja-Riitta Taskinen, MD, DMSC, Per-Henrik Groop, MD, DMSC, on behalf of the FinnDiane Study Group

Diabetes Care 2005;28(8):2019–2024

https://doi.org/10.2337/diacare.28.8.2019

Published: 01 August 2005

View article titled, Metabolic Syndrome in Type 1 Diabetes: <subtitle>Association with diabetic nephropathy and glycemic control (the FinnDiane study)</subtitle>

Journal Articles

IGF Binding Protein-1 and Carotid Intima-Media Thickness in Type 2 Diabetes: Response to Conti et al.

Eeva S. Leinonen, MD, Pekka J. Leinonen, MD, PHD, Marja-Riitta Taskinen, MD, PHD

Diabetes Care 2003;26(5):1654–1655

https://doi.org/10.2337/diacare.26.5.1654

Published: 01 May 2003

View article titled, IGF Binding Protein-1 and Carotid Intima-Media Thickness in Type 2 Diabetes: <subtitle>Response to Conti et al. </subtitle>

Journal Articles

Reduced IGFBP-1 Is Associated With Thickening of the Carotid Wall in Type 2 Diabetes

Eeva S. Leinonen, MD, Jukka T. Salonen, MD, PHD, Riitta M. Salonen, MD, PHD, Riitta A. Koistinen, PHD, Pekka J. Leinonen, MD, PHD, Seppo S. Sarna, PHD, Marja-Riitta Taskinen, MD, PHD

Diabetes Care 2002;25(10):1807–1812

https://doi.org/10.2337/diacare.25.10.1807

Published: 01 October 2002

View article titled, Reduced IGFBP-1 Is Associated With Thickening of the Carotid Wall in Type 2 Diabetes

Journal Articles

Fenofibrate Lowers Plasma Triglycerides and Increases LDL Particle Diameter in Subjects With Type 2 Diabetes

Juha Vakkilainen, MD, George Steiner, MD, Jean-Claude Ansquer, MD, Hëlinä Perttunen-Nio, MLT, Marja-Riitta Taskinen, MD

Diabetes Care 2002;25(3):627–628

https://doi.org/10.2337/diacare.25.3.627

Published: 01 March 2002

View article titled, Fenofibrate Lowers Plasma Triglycerides and Increases LDL Particle Diameter in Subjects With Type 2 Diabetes

Journal Articles

Differing Associations of Lipid and Lipoprotein Disturbances With the Macrovascular and Microvascular Complications of Type 1 Diabetes

Nish Chaturvedi, MRCP, John H. Fuller, FRCP, Marja-Riitta Taskinen, MD, On behalf of the EURODIAB PCS Group

Diabetes Care 2001;24(12):2071–2077

https://doi.org/10.2337/diacare.24.12.2071

Published: 01 December 2001

View article titled, Differing Associations of Lipid and Lipoprotein Disturbances With the Macrovascular and Microvascular Complications of Type 1 Diabetes

Journal Articles

Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome

Bo Isomaa, MD, Peter Almgren, MSC, Tiinamaija Tuomi, MD, Björn Forsén, MD, Kaj Lahti, MD, Michael Nissén, MD, Marja-Riitta Taskinen, MD, Leif Groop, MD

Diabetes Care 2001;24(4):683–689

https://doi.org/10.2337/diacare.24.4.683

Published: 01 April 2001

View article titled, Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome

Journal Articles

Comparison of Acute Daytime and Nocturnal Insulinization on Diurnal Glucose Homeostasis in NIDDM

Ilpo Puhakainen, MD, Marja-Riitta Taskinen, MD, Hannele Yki-Järvinen, MD

Diabetes Care 1994;17(8):805–809

https://doi.org/10.2337/diacare.17.8.805

Published: 01 August 1994

View article titled, Comparison of Acute Daytime and Nocturnal Insulinization on Diurnal Glucose Homeostasis in NIDDM

Journal Articles

Plasma Cholesteryl Ester Transfer Protein and Its Relationship to Plasma Lipoproteins and Apolipoprotein A-I-Containing Lipoproteins in IDDM Patients With Microalbuminuria and Clinical Nephropathy

Juhani Kahri, MD, Per-Henrik Groop, MD, Tom Elliott, MD, Giancarlo Viberti, MD, Marja-Riitta Taskinen, MD

Diabetes Care 1994;17(5):412–419

https://doi.org/10.2337/diacare.17.5.412

Published: 01 May 1994

View article titled, Plasma Cholesteryl Ester Transfer Protein and Its Relationship to Plasma Lipoproteins and Apolipoprotein A-I-Containing Lipoproteins in IDDM Patients With Microalbuminuria and Clinical Nephropathy

Journal Articles

Normalization of Lipoprotein Composition by Intraperitoneal Insulin in IDDM: Role of increased hepatic lipase activity

Giacomo Ruotolo, MD, Mariella Parlavecchia, PHD, Marja-Riitta Taskinen, MD, Gabriella Galimberti, MD, Adele Zoppo, MD, Ngoc-Anh Le, PHD, Francesca Ragogna, PHD, Piero Micossi, MD, Guido Pozza, MD

Diabetes Care 1994;17(1):6–12

https://doi.org/10.2337/diacare.17.1.6

Published: 01 January 1994

View article titled, Normalization of Lipoprotein Composition by Intraperitoneal Insulin in IDDM: Role of increased hepatic lipase activity

Journal Articles

Does Familial Hypertriglyceridemia Predispose to NIDDM?

Timo Sane, MD, Marja-Riitta Taskinen, MD

Diabetes Care 1993;16(11):1494–1501

https://doi.org/10.2337/diacare.16.11.1494

Published: 01 November 1993

View article titled, Does Familial Hypertriglyceridemia Predispose to NIDDM?

NARROW

Different Lipid Variables Predict Incident Coronary Artery Disease in Patients With Type 1 Diabetes With or Without Diabetic Nephropathy: The FinnDiane Study

HDL-C and HDL-C/ApoA-I Predict Long-Term Progression of Glycemia in Established Type 2 Diabetes

Glycemic Control Over 5 Years in 4,900 People With Type 2 Diabetes: Real-world diabetes therapy in a clinical trial cohort

Effects of Exenatide on Measures of β-Cell Function After 3 Years in Metformin-Treated Patients With Type 2 Diabetes

Exenatide Affects Circulating Cardiovascular Risk Biomarkers Independently of Changes in Body Composition

Effects of Long-Term Fenofibrate Treatment on Markers of Renal Function in Type 2 Diabetes: The FIELD Helsinki substudy

Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

One-Year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients: A randomized, controlled trial

The Increase of Apolipoprotein A-V During Postprandial Lipemia Parallels the Response of Triglyceride-Rich Lipoproteins in Type 2 Diabetes: No relationship between apoA-V and postheparin plasma lipolytic activity

Serum Lipids and the Progression of Nephropathy in Type 1 Diabetes

Metabolic Syndrome in Type 1 Diabetes: Association with diabetic nephropathy and glycemic control (the FinnDiane study)

IGF Binding Protein-1 and Carotid Intima-Media Thickness in Type 2 Diabetes: Response to Conti et al.

Reduced IGFBP-1 Is Associated With Thickening of the Carotid Wall in Type 2 Diabetes

Fenofibrate Lowers Plasma Triglycerides and Increases LDL Particle Diameter in Subjects With Type 2 Diabetes

Differing Associations of Lipid and Lipoprotein Disturbances With the Macrovascular and Microvascular Complications of Type 1 Diabetes

Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome

Comparison of Acute Daytime and Nocturnal Insulinization on Diurnal Glucose Homeostasis in NIDDM

Plasma Cholesteryl Ester Transfer Protein and Its Relationship to Plasma Lipoproteins and Apolipoprotein A-I-Containing Lipoproteins in IDDM Patients With Microalbuminuria and Clinical Nephropathy

Normalization of Lipoprotein Composition by Intraperitoneal Insulin in IDDM: Role of increased hepatic lipase activity

Does Familial Hypertriglyceridemia Predispose to NIDDM?

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

This Feature Is Available To Subscribers Only